Targeted therapy for fusion-driven high-risk acute leukemia.
Blood
; 132(12): 1241-1247, 2018 09 20.
Article
en En
| MEDLINE
| ID: mdl-30049809
Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend high-risk disease. Improved understanding of the molecular underpinnings of these fusions, coupled with novel chemistry approaches, now provide new opportunity for therapeutic inroads into the treatment of leukemia driven by these fusions.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Leucemia
/
Proteínas de Fusión Oncogénica
/
Inhibidores de Proteínas Quinasas
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Blood
Año:
2018
Tipo del documento:
Article